Search

Your search keyword '"Vaitkeviciene, Goda Elizabeta"' showing total 13 results
Start Over Author "Vaitkeviciene, Goda Elizabeta"
13 results on '"Vaitkeviciene, Goda Elizabeta"'

1. Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia

Author

Dam, Merete, Centanni, Maddalena, Friberg, Lena E., Centanni, Daniel, Karlsson, Mats O., Stensig Lynggaard, Line, Johannsdottir, Inga Maria, Wik, Hilde Skuterud, Malmros, Johan, Vaitkeviciene, Goda Elizabeta, Griskevicius, Laimonas, Hallböök, Helene, Jónsson, Ólafur Gísli, Overgaard, Ulrik, Schmiegelow, Kjeld, Hansen, Stefan Nygaard, Heyman, Mats, and Albertsen, Birgitte Klug

Published
2024
Full Text
View/download PDF

5. Pharmacokinetics and Immunogenicity of the First Doses of Peg-Asparaginase -an Alltogether Pilot Study

Author

Dam, Merete Eybye, primary, Centanni, Maddalena, additional, Friberg, Lena, additional, Karlsson, Mats, additional, Lynggaard, Line Stensig, additional, Johannsdottir, Inga M., additional, Wik, Hilde Skuterud, additional, Heyman, Mats, additional, Malmros, Johan, additional, Hallböök, Helene, additional, Vaitkeviciene, Goda Elizabeta, additional, Griskevicius, Laimonas, additional, Jónsson, Ólafur Gísli, additional, Overgaard, Ulrik Malthe, additional, Schmiegelow, Kjeld, additional, and Albertsen, Birgitte Klug, additional

Published
2022
Full Text
View/download PDF

7. NOR-GRASPALL2016 (NCT03267030): Asparaginase Encapsulated in Erythrocytes (eryaspase) - a Promising Alternative to Peg-Asparaginase in Case of Hypersensitivity

Author

Lynggaard, Line Stensig, primary, Gottschalk Højfeldt, Sofie, additional, Moeller, Lisbeth, additional, Vaitkeviciene, Goda Elizabeta, additional, Langenskiöld, Cecilia, additional, Lehmann, Anne Kristine, additional, Lepik, Kristi, additional, Lähteenmäki, Päivi Maria, additional, Schmiegelow, Kjeld, additional, and Albertsen, Birgitte Klug, additional

Published
2020
Full Text
View/download PDF

9. Value of Flow Cytometry for MRD-Based Relapse Prediction in B-Cell Precursor Acute Lymphoblastic Leukemia in a Multi-Center Setting

Author

Modvig, Signe, primary, Madsen, Hans, additional, Hallböök, Helene, additional, Siitonen, Sanna M., additional, Osnes, Liv T. N., additional, Rosthøj, Susanne, additional, Tierens, Anne, additional, Juvonen, Vesa, additional, Vålerhaugen, Helen, additional, Hultdin, Magnus, additional, Ehinger, Mats, additional, Porwit, Anna, additional, Matuzeviciene, Reda, additional, Stoskus, Mindaugas, additional, Marincevic, M, additional, Lilleorg, Aili, additional, Taskinen, Mervi, additional, Toft, Nina, additional, Jónsson, Ólafur Gísli, additional, Pruunsild, Kaie, additional, Vaitkeviciene, Goda Elizabeta, additional, Vettenranta, Kim, additional, Lund, Bendik, additional, Abrahamsson, Jonas, additional, Schmiegelow, Kjeld, additional, and Marquart, Hanne Vibeke, additional

Published
2019
Full Text
View/download PDF

10. Asparaginase-Associated Pancreatitis in ALL: Results from the NOPHO ALL2008 Treatment of Patients 1-45 Years

Author

Rank, Cecilie Utke, primary, Wolthers, Benjamin Ole, additional, Grell, Kathrine, additional, Albertsen, Birgitte Klug, additional, Frandsen, Thomas Leth, additional, Overgaard, Ulrik Malthe, additional, Toft, Nina, additional, Nielsen, Ove Juul, additional, Wehner, Peder Skov, additional, Harila-Saari, Arja, additional, Heyman, Mats, additional, Abrahamsson, Jonas, additional, Norén-Nyström, Ulrika, additional, Tomaszewska-Toporska, Beata, additional, Lund, Bendik, additional, Jarvis, Kirsten Brunsvig, additional, Quist-Paulsen, Petter, additional, Vaitkeviciene, Goda Elizabeta, additional, Griškevičius, Laimonas, additional, Taskinen, Mervi, additional, Wartiovaara-Kautto, Ulla, additional, Lepik, Kristi, additional, Punab, Mari, additional, Jónsson, Ólafur Gísli, additional, and Schmiegelow, Kjeld, additional

Published
2019
Full Text
View/download PDF

12. Evaluation of oncofertility care in childhood cancer patients: the EU-Horizon 2020 twinning project TREL initiative.

Author

Stukaite-Ruibiene E, van der Perk MEM, Vaitkeviciene GE, Bos AME, Bumbuliene Z, van den Heuvel-Eibrink MM, and Rascon J

Abstract

Background: The 5-year survival rate of childhood cancer exceeds 80%, however, many survivors develop late effects including infertility. The aim of this study was to evaluate the current status of oncofertility care at Vilnius University Hospital Santaros Klinikos (VULSK) within the framework of the EU-Horizon 2020 TREL project., Methods: All parents or patients aged 12-17.9 years treated from July 1, 2021 until July 1, 2022 were invited to complete an oncofertility-care-evaluation questionnaire. After completing the questionnaire, patients were triaged to low-risk (LR) or high-risk (HR) of gonadal damage using a risk stratification tool (triage). Data was assessed using descriptive statistics., Results: Questionnaires were completed by 48 parents and 13 children triaged as 36 (59%) LR and 25 (41%) HR patients. Most HR respondents (21/25, 84%) were not counseled by a fertility specialist. Six boys (4 HR, 2 LR) were counseled, none of the girls was counseled. Three HR boys underwent sperm cryopreservation. Only 17 (27.9%, 9 HR, 8 LR) respondents correctly estimated their risk. All counseled boys ( n  = 6) agreed the risk for fertility impairment had been mentioned as compared to 49.1% ( n  = 27) of uncounseled. All counseled respondents agreed they knew enough about fertility (vs. 42%)., Conclusions: Respondents counseled by a fertility specialist were provided more information on fertility than uncounseled. HR patients were not sufficiently counseled by a fertility specialist. Based on the current experience oncofertility care at VULSK will be improved., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (© 2023 Stukaite-Ruibiene, van der Perk, Vaitkeviciene, Bos, Bumbuliene, van den Heuvel-Eibrink and Rascon.)

Published
2023
Full Text
View/download PDF

13. Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic NUP214 :: ABL1 Gene Fusion.

Author

Stukaite-Ruibiene E, Norvilas R, Dirse V, Stankeviciene S, and Vaitkeviciene GE

Subjects
Adolescent, Benzamides, Gene Fusion, Humans, Imatinib Mesylate therapeutic use, Nuclear Pore Complex Proteins genetics, Oncogene Proteins, Fusion genetics, Oncogene Proteins, Fusion metabolism, Piperazines pharmacology, Protein Kinase Inhibitors pharmacology, Protein Kinase Inhibitors therapeutic use, Protein Kinases genetics, Protein Kinases metabolism, Pyrimidines therapeutic use, Antineoplastic Agents therapeutic use, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics
Abstract

Acute lymphoblastic leukemia (ALL) with recurrent genetic lesions, affecting a series of kinase genes, is associated with unfavorable prognosis, however, it could benefit from treatment with tyrosine kinase inhibitors (TKI). NUP214 :: ABL1 fusion is detected in 6% of T-cell acute lymphoblastic leukemia (T-ALL), and is very rare in B-ALL. We present a case of adolescent with B-ALL and a cryptic NUP214 :: ABL1 fusion which was initially missed during diagnostic screening and was detected by additional RNA sequencing. Treatment with specific ABL-inhibitor Imatinib was added later in therapy with a good effect. Initial treatment according to conventional chemotherapy was complicated by severe side effects. At the end of Consolidation, the patient was stratified to a high risk group with allogeneic hematopoietic stem cell transplantation because of insufficient response to therapy. At that time, targeted RNA sequencing detected NUP214 :: ABL1 gene fusion which was previously missed due to a small microduplication in the 9q34 chromosome region. Gene variant analysis revealed no TKI-resistant ABL1 mutations; therefore, treatment with Imatinib was added to target the NUP214::ABL1 fusion protein. A negative minimal residual disease was achieved, and treatment was downgraded to intermediate risk protocol. Combining routine genetic assays with next-generation sequencing methods could prevent from missing atypical gene alterations. Identification of rare targetable genetic subtypes is of importance in order to introduce targeted therapy as early as possible that may improve survival and reduce toxicity. Treatment with ABL1 inhibitor imatinib mesylate revealed as a highly effective targeted therapy against the leukemia driving protein kinase., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Stukaite-Ruibiene, Norvilas, Dirse, Stankeviciene and Vaitkeviciene.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results